As per a recent study by Foer et al., adult patients with moderate to severe asthma and diabetes mellitus who were treated with glucagon-like peptide-1 receptor agonists (GLP1-RAs) experienced fewer asthma exacerbations over a 6-month period compared to those receiving treatment with insulin, DPP4 inhibitors, or sulfonylureas. Here, INS is linked to asthma.